HEXTEND APPROVED FOR SALE IN CANADA

BERKELEY, Calif.--July 9, 2002--BioTime, Inc. (AMEX:BTX) announced today that Hextend(R) has been approved for sale in Canada. Hextend is BioTime's proprietary hetastarch-based plasma volume expander with lactate, multiple electrolytes, and physiological amounts of glucose. Hextend will be marketed in Canada by Abbott Laboratories, Limited, Canada, an affiliate of Abbott International. Dr. Paul Segall, BioTime's chairman and chief executive officer, stated, "We are very pleased to report that BioTime has received a Notice of Compliance from the Health Products and Food Branch, Health Canada, regarding our application to market Hextend. Although Hextend is currently approved for sale and used in hundreds of leading hospitals in the United States, Canadian approval represents its first in another country."

"The success of Hextend in the United States and its pending introduction in Canada may facilitate its entrance into many new markets throughout the world," said Dr. Segall. "Abbott Laboratories currently manufactures and markets Hextend in the United States. Hextend's Canadian approval strengthens and broadens our productive relationship with this prestigious member of the world's pharmaceutical industry."

About BioTime, Inc.
BioTime, headquartered in Berkeley, California develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment, and other applications. Information about BioTime can be found on the web at www.biotimeinc.com .

The matters discussed in this press release include forward-looking statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the results of clinical trials of BioTime products; BioTime's ability to obtain FDA and foreign regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of and demand for BioTime's products; BioTime's ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; the availability of ingredients used in BioTime products; and the availability of reimbursement for the cost of BioTime products (and related treatment) from government health administration authorities, private health coverage insurers and other organizations. These and other risk factors are discussed in BioTime's Annual Report on Form 10-K filed with the Securities and Exchange Commission.

CONTACT:
BioTime, Inc., Berkeley
Judith Segall, 510/845-9535
or
Padilla Speer Beardsley
Malkie Bernheim, 212/752-8338
mbernheim@psbpr.com